Company intelligence / Profile preview

CaaMTech

Issaquah, Washington, United Statescaam.tech ↗

Ownership: Private
Development stage: Preclinical

Overview

CaaMTech has synthesized and characterized hundreds of novel serotonergic compounds. Its lead program, CT-4201—a psilocin prodrug with improved pharmacokinetics—has received positive regulatory feedback for its clinical trial design targeting major depressive disorder. The company spun out Transneural Therapeutics in April 2025 to focus on non-hallucinogenic neuroplastogens for neuropsychiatric and neurodegenerative diseases.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

CT-4201

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Research collaborations with several research centers including Leibniz Institutes in Germany and UMass DartmouthNo major pharma partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on CaaMTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CaaMTech.

Explore the full profile